Abstract
Purpose
Sexual dysfunction is an important concern of premenopausal women with early breast cancer. We investigated predictors of sexual problems in two randomized controlled trials.
Methods
A subset of patients enrolled in TEXT and SOFT completed global and symptom-specific quality-of-life indicators, CES-Depression and MOS-Sexual Problems measures at baseline, six, 12 and 24 months. Mixed models tested the association of changes in treatment-induced symptoms (baseline to 6 months), depression at 6 months, and age at randomization with changes in sexual problems over 2 years.
Results
Sexual problems increased by 6 months and persisted at this level. Overall, patients with more severe worsening of vaginal dryness, sleep disturbances and bone or joint pain at 6 months reported a greater increase in sexual problems at all time-points. Depression scores were significantly associated with sexual problems in the short-term. All other symptoms had a smaller impact on sexual problems. Age was not associated with sexual problems at any time-point.
Conclusion
Among several key symptoms, vaginal dryness, sleep disturbance, and bone and joint pain significantly predicted sexual problems during the first 2 years. Early identification of these symptoms may contribute to timely and tailored interventions.
Similar content being viewed by others
Data availability
The data on which these analyses are based forms part of the clinical trials database of the International Breast Cancer Study Group, and as such is available for use on application in accordance with IBCSG data sharing policy.
References
Bober SL, Varela VS (2012) Sexuality in adult cancer survivors: challenges and intervention. J Clin Oncol 30(30):3712–3719. https://doi.org/10.1200/JCO.2012.41.7915
Schover LR, van der Kaaij M, van Dorst E, Creutzberg C, Huyghe E, Kiserud CE (2014) Sexual dysfunction and infertility as late effects of cancer treatment. EJC Suppl 12(1):41–53. https://doi.org/10.1016/j.ejcsup.2014.03.004
Kedde H, van de Wiel HB, Weijmar Schultz WC, Wijsen C (2013) Sexual dysfunction in young women with breast cancer. Support Care Cancer 21(1):271–280. https://doi.org/10.1007/s00520-012-1521-9
Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS (2013) Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 20(2):162–168. https://doi.org/10.1097/gme.0b013e31826560da
Frechette D, Paquet L, Verma S, Clemons M, Wheatley-Price P, Gertler SZ, Song X, Graham N, Dent S (2013) The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study. Breast Cancer Res Treat 141(1):111–117. https://doi.org/10.1007/s10549-013-2659-y
Raggio GA, Butryn ML, Arigo D, Mikorski R, Palmer SC (2014) Prevalence and correlates of sexual morbidity in long-term breast cancer survivors. Psychol Health 29(6):632–650. https://doi.org/10.1080/08870446.2013.879136
Maiorino MI, Chiodini P, Bellastella G, Giugliano D, Esposito K (2016) Sexual dysfunction in women with cancer: a systematic review with meta-analysis of studies using the Female Sexual Function Index. Endocrine 54(2):329–341. https://doi.org/10.1007/s12020-015-0812-6
Davis SR, Panjari M, Robinson PJ, Fradkin P, Bell RJ (2014) Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis. Menopause 21(10):1075–1081. https://doi.org/10.1097/GME.0000000000000219
Oberguggenberger A, Martini C, Huber N, Fallowfield L, Hubalek M, Daniaux M, Sperner-Unterweger B, Holzner B, Sztankay M, Gamper E, Meraner V (2017) Self-reported sexual health: breast cancer survivors compared to women from the general population—an observational study. BMC Cancer 17(1):599. https://doi.org/10.1186/s12885-017-3580-2
Aerts L, Christiaens MR, Enzlin P, Neven P, Amant F (2014) Sexual functioning in women after mastectomy versus breast conserving therapy for early-stage breast cancer: a prospective controlled study. Breast 23(5):629–636. https://doi.org/10.1016/j.breast.2014.06.012
Boquiren VM, Esplen MJ, Wong J, Toner B, Warner E, Malik N (2016) Sexual functioning in breast cancer survivors experiencing body image disturbance. Psychooncology 25(1):66–76. https://doi.org/10.1002/pon.3819
Schover LR (2008) Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol 26(5):753–758. https://doi.org/10.1200/JCO.2007.14.1655
Rosenberg SM, Tamimi RM, Gelber S, Ruddy KJ, Bober SL, Kereakoglow S, Borges VF, Come SE, Schapira L, Partridge AH (2014) Treatment-related amenorrhea and sexual functioning in young breast cancer survivors. Cancer 120(15):2264–2271. https://doi.org/10.1002/cncr.28738
Berglund G, Nystedt M, Bolund C, Sjoden PO, Rutquist LE (2001) Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol 19(11):2788–2796. https://doi.org/10.1200/JCO.2001.19.11.2788
Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Puglisi F, Pavesi L, Parmar V, Regan MM, Pagani O, Fleming GF, Francis PA, Price KN, Coates AS, Gelber RD, Goldhirsch A, Walley BA (2015) Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol 16(7):848–858. https://doi.org/10.1016/S1470-2045(15)00049-2
Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, Wagner LI, Martino S, Ingle JN, Sparano JA, Solin LJ, Wood WC, Robert NJ (2014) Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 32(35):3948–3958. https://doi.org/10.1200/JCO.2014.55.6993
Ribi K, Luo W, Bernhard J, Francis PA, Burstein HJ, Ciruelos E, Bellet M, Pavesi L, Lluch A, Visini M, Parmar V, Tondini C, Kerbrat P, Perello A, Neven P, Torres R, Lombardi D, Puglisi F, Karlsson P, Ruhstaller T, Colleoni M, Coates AS, Goldhirsch A, Price KN, Gelber RD, Regan MM, Fleming GF (2016) Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial. J Clin Oncol 34(14):1601–1610. https://doi.org/10.1200/JCO.2015.64.8675
Avis NE, Johnson A, Canzona MR, Levine BJ (2018) Sexual functioning among early post-treatment breast cancer survivors. Support Care Cancer 26(8):2605–2613. https://doi.org/10.1007/s00520-018-4098-0
Lee M, Kim YH, Jeon MJ (2015) Risk factors for negative impacts on sexual activity and function in younger breast cancer survivors. Psychooncology 24(9):1097–1103. https://doi.org/10.1002/pon.3772
Speer JJ, Hillenberg B, Sugrue DP, Blacker C, Kresge CL, Decker VB, Zakalik D, Decker DA (2005) Study of sexual functioning determinants in breast cancer survivors. Breast J 11(6):440–447. https://doi.org/10.1111/j.1075-122X.2005.00131.x
Bredart A, Dolbeault S, Savignoni A, Besancenet C, This P, Giami A, Michaels S, Flahault C, Falcou MC, Asselain B, Copel L (2011) Prevalence and associated factors of sexual problems after early-stage breast cancer treatment: results of a French exploratory survey. Psychooncology 20(8):841–850. https://doi.org/10.1002/pon.1789
Landi SN, Doll KM, Bensen JT, Hendrix L, Anders CK, Wu JM, Nichols HB (2016) Endocrine therapy and urogenital outcomes among women with a breast cancer diagnosis. Cancer Causes Control 27(11):1325–1332. https://doi.org/10.1007/s10552-016-0810-x
Soldera SV, Ennis M, Lohmann AE, Goodwin PJ (2018) Sexual health in long-term breast cancer survivors. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-018-4894-8
Perez M, Liu Y, Schootman M, Aft RL, Schechtman KB, Gillanders WE, Jeffe DB (2010) Changes in sexual problems over time in women with and without early-stage breast cancer. Menopause 17(5):924–937. https://doi.org/10.1097/gme.0b013e3181d5dd26
Marino JL, Saunders CM, Emery LI, Green H, Doherty DA, Hickey M (2016) How does adjuvant chemotherapy affect menopausal symptoms, sexual function, and quality of life after breast cancer? Menopause 23(9):1000–1008. https://doi.org/10.1097/GME.0000000000000664
Panjari M, Bell RJ, Davis SR (2011) Sexual function after breast cancer. J Sex Med 8(1):294–302. https://doi.org/10.1111/j.1743-6109.2010.02034.x
van Londen GJ, Beckjord EB, Dew MA, Cooper KL, Davidson NE, Bovbjerg DH, Donovan HS, Thurston RC, Morse JQ, Nutt S, Rechis R (2014) Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors. Support Care Cancer 22(4):937–945. https://doi.org/10.1007/s00520-013-2041-y
Hummel SB, Hahn DEE, van Lankveld J, Oldenburg HSA, Broomans E, Aaronson NK (2017) Factors associated with specific diagnostic and statistical manual of mental disorders, fourth edition sexual dysfunctions in breast cancer survivors: a study of patients and their partners. J Sex Med 14(10):1248–1259. https://doi.org/10.1016/j.jsxm.2017.08.004
Robinson PJ, Bell RJ, Christakis MK, Ivezic SR, Davis SR (2017) Aromatase inhibitors are associated with low sexual desire causing distress and fecal incontinence in women: an observational study. J Sex Med 14(12):1566–1574. https://doi.org/10.1016/j.jsxm.2017.09.018
Gandhi C, Butler E, Pesek S, Kwait R, Edmonson D, Raker C, Clark MA, Stuckey A, Gass J (2019) Sexual dysfunction in breast cancer survivors: is it surgical modality or adjuvant therapy? Am J Clin Oncol 42(6):500–506. https://doi.org/10.1097/COC.0000000000000552
Burwell SR, Case LD, Kaelin C, Avis NE (2006) Sexual problems in younger women after breast cancer surgery. J Clin Oncol 24(18):2815–2821. https://doi.org/10.1200/JCO.2005.04.2499
Paiva CE, Rezende FF, Paiva BS, Mauad EC, Zucca-Matthes G, Carneseca EC, Syrjanen KJ, Schover LR (2016) Associations of body mass index and physical activity with sexual dysfunction in breast cancer survivors. Arch Sex Behav 45:2057–2068. https://doi.org/10.1007/s10508-016-0758-7
Rojas KE, Matthews N, Raker C, Clark MA, Onstad M, Stuckey A, Gass J (2018) Body mass index (BMI), postoperative appearance satisfaction, and sexual function in breast cancer survivorship. J Cancer Surviv 12(1):127–133. https://doi.org/10.1007/s11764-017-0651-y
Den Oudsten BL, Van Heck GL, Van der Steeg AF, Roukema JA, De Vries J (2010) Clinical factors are not the best predictors of quality of sexual life and sexual functioning in women with early stage breast cancer. Psychooncology 19(6):646–656. https://doi.org/10.1002/pon.1610
Morrow PK, Broxson AC, Munsell MF, Basen-Enquist K, Rosenblum CK, Schover LR, Nguyen LH, Hsu L, Castillo L, Hahn KM, Litton JK, Kwiatkowski DN, Hortobagyi GN (2014) Effect of age and race on quality of life in young breast cancer survivors. Clin Breast Cancer 14(2):e21–31. https://doi.org/10.1016/j.clbc.2013.10.003
Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA, TEXT, and SOFT Investigators; International Breast Cancer Study Group (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371(2):107–118. https://doi.org/10.1056/NEJMoa1404037
Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD, SOFT Investigators; International Breast Cancer Study Group (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372(5):436–446. https://doi.org/10.1056/NEJMoa1412379
Sherbourne CD (1992) Social functioning: sexual problems measures. In: Stewart AL, Ware JE (eds) Measuring functioning and well-being: the medical outcomes study approach. Duke University Press, Durham, pp 194–204
Bartula I, Sherman KA (2013) Screening for sexual dysfunction in women diagnosed with breast cancer: systematic review and recommendations. Breast Cancer Res Treat 141(2):173–185. https://doi.org/10.1007/s10549-013-2685-9
Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N (2016) Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387(10021):857–865. https://doi.org/10.1016/S0140-6736(15)01169-1
Sloan JA, Dueck A (2004) Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat 14(1):73–96. https://doi.org/10.1081/BIP-120028507
Bernhard J, Hurny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Senn HJ, Rudenstam CM (1997) Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group. Ann Oncol 8(9):825–835. https://doi.org/10.1023/A:1008269715091
Bernhard J, Sullivan M, Hurny C, Coates AS, Rudenstam CM (2001) Clinical relevance of single item quality of life indicators in cancer clinical trials. Br J Cancer 84(9):1156–1165. https://doi.org/10.1054/bjoc.2001.1785
Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hurny C, Gelber RD, Forbes JF, Murray E, Collins J, Aebi S, Thurlimann B, Price KN, Goldhirsch A, Coates AS, International Breast Cancer Study Group Trial V (2007) Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients—the International Breast Cancer Study Group Trial VIII. J Clin Oncol 25(3):263–270. https://doi.org/10.1200/JCO.2005.04.5393
Radloff LS (1977) The CES-D Scale: a self-reported depression scale for research in the general population. Appl Psychol Meas 1:385–401
Wakefield CE, Butow PN, Aaronson NA, Hack TF, Hulbert-Williams NJ, Jacobsen PB, International Psycho-Oncology Society Research Committee (2015) Patient-reported depression measures in cancer: a meta-review. Lancet Psychiatry 2(7):635–647. https://doi.org/10.1016/S2215-0366(15)00168-6
von Hippel C, Rosenberg SM, Austin SB, Sprunck-Harrild K, Ruddy KJ, Schapira L, Come S, Borges VF, Partridge AH (2019) Identifying distinct trajectories of change in young breast cancer survivors' sexual functioning. Psychooncology 28(5):1033–1040. https://doi.org/10.1002/pon.5047
Ganz PA, Desmond KA, Belin TR, Meyerowitz BE, Rowland JH (1999) Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 17(8):2371–2380. https://doi.org/10.1200/JCO.1999.17.8.2371
Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, Sharer CW, Burton GV, Kuzma CS, Moseley A, Lew DL, Fisch MJ, Moinpour CM, Hershman DL, Wade JL 3rd (2018) Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202. J Clin Oncol 36(4):326–332. https://doi.org/10.1200/JCO.2017.74.6651
Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, Fiellin M, Capozza S, Rothbard M, Zhou Y, Harrigan M, Sanft T, Schmitz K, Neogi T, Hershman D, Ligibel J (2015) Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 33(10):1104–1111. https://doi.org/10.1200/JCO.2014.57.1547
Carter J, Lacchetti C, Andersen BL, Barton DL, Bolte S, Damast S, Diefenbach MA, DuHamel K, Florendo J, Ganz PA, Goldfarb S, Hallmeyer S, Kushner DM, Rowland JH (2018) Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. J Clin Oncol 36(5):492–511. https://doi.org/10.1200/JCO.2017.75.8995
Hayes RD, Dennerstein L, Bennett CM, Sidat M, Gurrin LC, Fairley CK (2008) Risk factors for female sexual dysfunction in the general population: exploring factors associated with low sexual function and sexual distress. J Sex Med 5(7):1681–1693. https://doi.org/10.1111/j.1743-6109.2008.00838.x
Brotto L, Atallah S, Johnson-Agbakwu C, Rosenbaum T, Abdo C, Byers ES, Graham C, Nobre P, Wylie K (2016) Psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med 13(4):538–571. https://doi.org/10.1016/j.jsxm.2016.01.019
Reichenpfader U, Gartlehner G, Morgan LC, Greenblatt A, Nussbaumer B, Hansen RA, Van Noord M, Lux L, Gaynes BN (2014) Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf 37(1):19–31. https://doi.org/10.1007/s40264-013-0129-4
Saha P, Regan MM, Pagani O, Francis PA, Walley BA, Ribi K, Bernhard J, Luo W, Gomez HL, Burstein HJ, Parmar V, Torres R, Stewart J, Bellet M, Perello A, Dane F, Moreira A, Vorobiof D, Nottage M, Price KN, Coates AS, Goldhirsch A, Gelber RD, Colleoni M, Fleming GF, SOFT; TEXT Investigators; International Breast Cancer Study Group (2017) Treatment efficacy, adherence, and quality of life among women younger than 35 years in the international breast cancer study group TEXT and SOFT adjuvant endocrine therapy trials. J Clin Oncol 35(27):3113–3122. https://doi.org/10.1200/JCO.2016.72.0946
Jeffery DD, Tzeng JP, Keefe FJ, Porter LS, Hahn EA, Flynn KE, Reeve BB, Weinfurt KP (2009) Initial report of the cancer Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function committee: review of sexual function measures and domains used in oncology. Cancer 115(6):1142–1153. https://doi.org/10.1002/cncr.24134
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington DC
World Health Organization (2004) International classification of diseases and health related problems. World Health Organization, Geneva
Hendrickx L, Gijs L, Enzlin P (2013) Distress, sexual dysfunctions, and DSM: dialogue at cross purposes? J Sex Med 10(3):630–641. https://doi.org/10.1111/j.1743-6109.2012.02971.x
Safarinejad MR, Shafiei N, Safarinejad S (2013) Quality of life and sexual functioning in young women with early-stage breast cancer 1 year after lumpectomy. Psychooncology 22(6):1242–1248. https://doi.org/10.1002/pon.3130
Razdan SN, Patel V, Jewell S, McCarthy CM (2016) Quality of life among patients after bilateral prophylactic mastectomy: a systematic review of patient-reported outcomes. Qual Life Res 25(6):1409–1421. https://doi.org/10.1007/s11136-015-1181-6
Bai L, Arver B, Johansson H, Sandelin K, Wickman M, Brandberg Y (2019) Body image problems in women with and without breast cancer 6–20 years after bilateral risk-reducing surgery–a prospective follow-up study. Breast 44:120–127. https://doi.org/10.1016/j.breast.2019.01.013
Acknowledgements
We thank the patients, physicians, nurses and trial coordinators who participated in the SOFT and TEXT clinical trials. The trials were coordinated by the International Breast Cancer Study Group (IBCSG), in collaboration with the Breast International Group (BIG), BIG cooperative groups, and US National Cancer Institute, National Clinical Trials Network cooperative groups.
Funding
SOFT and TEXT receive financial support for trial conduct from Pfizer, the International Breast Cancer Study Group, the US National Cancer Institute, the Breast Cancer Research Foundation (16-185, 17-187, 18-003), Ipsen, TerSera. Pfizer and Ipsen provided drug supply.
Support for the coordinating group, IBCSG: Frontier Science and Technology Research Foundation, Swiss Group for Clinical Cancer Research (SAKK), Cancer Research Switzerland, Oncosuisse, Cancer League Switzerland, Foundation for Clinical Cancer Research of Eastern Switzerland (OSKK). Grant support of cooperative groups: Breast Cancer Trials Australia & New Zealand [NHMRC 351161, 510788 and 1105058]; Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) on behalf of the National Cancer Research Institute Breast Clinical Studies Group United Kingdom (NCRI-BCSG—ICR-CTSU Partnership) [Cancer Research UK CRUKE/03/022, CRUKE/03/023, A15955; National Institute for Health Research Royal Marsden/Institute of Cancer Research Biomedical Research Centre; and National Institute for Health Research/Cambridge Biomedical Research Centre; Alliance for Clinical Trials in Oncology [US NIH U10CA180821]; SWOG [US NIH CA32102]; ECOG-ACRIN Cancer Research Group [US NIH CA21115, CA16116]; NRG Oncology [US NIH grant numbers U10CA180868, U10CA180822, UG1CA189867]; Canadian Cancer Trials Group [US NIH CA077202; and Canadian Cancer Society Research Institute 015469, 021039].
Author information
Authors and Affiliations
Contributions
Karin Ribi, Weixiu Luo, Prue Francis, Gini F. Fleming, Olivia Pagani, Barbara A. Wallley Richard D. Gelber, Aron Goldhirsch, Alan S. Coates, Meredith M. Regan, Jürg Bernhard—Conception and design. Barbara A. Walley, Harold J. Burstein, Michael J. Naughton, Jacquie Chirgwin, Rafat H. Ansari, Muhammed Salim, Andre van der Westhuizen, Ehtesham Abdi, Prudence A. Francis, Daniel R. Budman, Stephen Chia, Hagen Kennecke, Vernon J. Harvey, Anita Giobbie-Hurder, Gini F. Fleming, Olivia Pagani, Angelo Di Leo, Marco Colleoni, Richard D. Gelber, Aron Goldhirsch, Alan S. Coates, Meredith M. Regan—Collection and assembly of data. Barbara A. Walley, Harold J. Burstein, Michael J. Naughton, Jacquie Chirgwin, Rafat H. Ansari, Muhammed Salim, Andre van der Westhuizen, Ehtesham Abdi, Prudence A. Francis, Daniel R. Budman, Stephen Chia, Hagen Kennecke, Vernon J. Harvey, Anita Giobbie-Hurder, Gini F. Fleming, Olivia Pagani, Angelo Di Leo, Marco Colleoni, Richard D. Gelber, Aron Goldhirsch, Alan S. Coates, Meredith M. Regan—provision of study materials or patients. Karin Ribi, Weixiu Luo, Alan S. Coates, Richard D. Gelber, Meredith M. Regan, Jürg Bernhard—Data analysis and interpretation. All authors—Manuscript writing and final approval of manuscript.
Corresponding author
Ethics declarations
Conflict of interest
KR, WL, BAW, HJB, JC, RHA, MS, AvW, EA, VJH, AGH, OP, AG, ASC, and JB have nothing to disclose. PAF reports personal fees from AstraZeneca, personal fees from Novartis, outside the submitted work; and Presentation of SOFT and TEXT trial results for Pfizer and Ipsen at overseas meeting without receiving honorarium. SC reports grants from NCIC, during the conduct of the study. GFF reports personal fees from Up To Date and Vaniam Group, non-financial support from Corcept, other from Merck, Syndax, 47 Inc, Sanofi, Astex EMD Sereno, Roche/Genentech, Syros, Tesaro, Iovance, Sanofi, Ssermonix, Incyte, Compugen and Abbvie, outside the submitted work. AD reports personal fees from AstraZeneca, personal fees from Bayer, personal fees from Celgene, personal fees from Daichii-Sankyo, personal fees from Eisai, personal fees from Genentech, personal fees from Genomic Health, personal fees from Ipsen, personal fees from Lilly, grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Pierre Fabre, personal fees from Roche, personal fees from Seattle Genetics, outside the submitted work. MC reports personal fees from AstraZeneca, personal fees from Pierre Fabre, personal fees from Pfizer, personal fees from Novartis, personal fees from OBI Pharma, personal fees from Puma Biotechnology, personal fees from Celldex, outside the submitted work. RDG reports grants from Pfizer, grants from Ipsen, grants from AstraZeneca, during the conduct of the study; grants from Roche, grants from Merck, grants from Celgene, grants from Ferring, grants from Novartis, outside the submitted work. MMR reports grants and non-financial support from Pfizer, non-financial support and other from Ipsen, during the conduct of the study; grants and non-financial support from Research funding to the IBCSG (and/or provision of drug supply for clinical trials) from Novartis, Pfizer, Ipsen, TerSera, Merck, Ferring, Pierre Fabre, Roche, AstraZeneca, grants from Bayer, grants and personal fees from Bristol-Myers Squibb, outside the submitted work.
Ethics approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Ethics committees and appropriate national health authorities from each center approved the protocol, and all patients provided written informed consent as part of the informed consent for the main trial. This manuscript does not contain any individual person’s data in any form.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Trial Registration: clinicaltrials.gov NCT00066703 (TEXT) and NCT00066690 (SOFT).
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ribi, K., Luo, W., Walley, B.A. et al. Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. Breast Cancer Res Treat 181, 347–359 (2020). https://doi.org/10.1007/s10549-020-05622-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-020-05622-5